This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015. doi:10.1007/s10157-015-1086-2.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.
Kawada T. Validating GFR estimating samples with clinical outcomes. Am J Kidney Dis. 2014;63:859.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.
Conflict of interest
The author has indicated no financial support. The author has declared that no conflict of interest exists.
About this article
Cite this article
Kawada, T. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol 20, 147–148 (2016). https://doi.org/10.1007/s10157-015-1134-y